.5) was used as several different preparations and doses [ie, reduced alkylated human immunoglobulin (Polyglobin ® , Bayel Yakuhin Ltd), 17 pH4 stabilized acid human immunoglobulin (Polyglobin N ® , Bayel Yakuhin Ltd), 18 polyethyleneglycol-treated human immunoglobulin (Venoglobulin IH ® , Mitsubishi-Welpharma Ltd) and sulfonated human immunoglobulin (Venilon ® , Teijin Ltd) 19 ] (Table 1) . Although polyethyleneglycoltreated human immunoglobulin and sulfonated human immunoglobulin were assigned to the same randomized multicenter control study, reduced alkylated human immunoglobulin and pH4 stabilized acid human immunoglobulin were registered individually in different randomized multicenter control studies at different times. The dosage of GG used in high-dose therapy was either 100, 200, or 400 mg/kg per day for 5 days. Reduced alkylated human immunoglobulin and pH4 stabilized acid human immunoglobulin were combined with aspirin 10 mg/kg per day, and polyethyleneglycol-treated human immunoglobulin and sulfonated human immunoglobulin were combined with aspirin (30 mg/kg per day) in the acute stage followed by 10 mg/kg per day after the body temperature had improved. Randomization by a central registration system was performed by the envelope method in the first 2 trials, in which the controller made a layout of 3 kinds of dosage at random for 3 cases in an envelope, and by the minimization method in the last trial using age class, sex and study center as the prognostic factors for balancing. Therapy with aspirin alone (A) was included in each GG trial for comparison, and also used in 1980-1986 between the steroids era and GG era. Clinical trials were approved by the committee of the medical ethics in each hospital. Non-specific therapy (Non) for KD, such as antibiotics, was administered to patients who were not diagnosed until the convalescent stage.
Although aspirin was initially used for prophylaxis against the transformation of aneurysms into stenotic lesions, aspirin and warfarin was used for the treatment of giant aneurysms after 1988. The standard amount of aspirin (10 mg/kg per day) and warfarin (0.1 mg/kg per day) were adjusted with the thrombotest approximately 30% and also adjusted if severe ecchymosis or microscopic hematuria developed or when thrombus formation in an aneurysm was observed on routine follow-up echocardiography for older children. The thrombotest was generally performed annually. For younger children, however, the dosage was changed according to body weight, following a thrombotest every 3-6 months.
Antiobstructive prophylaxis was classified into aspirin alone or aspirin plus dipiridamole {a}, warfarin {w}, aspirin and warfarin {aw}, or no prophylaxis {n} ( Table 2) . Prophylaxis {a} included both aspirin alone and aspirin plus dipyridamole because there was no significant difference in the antiplatelet effect. 20 The effect of the prophylaxis against transformation into stenotic lesions was compared by each therapeutic regimen in the acute stage.
CAG, prior to the use of echocardiography, 21 was performed 2-3 months after the onset of KD, then every 1-2 years and 3-4 years after onset, prior to entering elementary school and a few years later. After the introduction of echocardiography, CAG was no longer performed 2-3 months after onset and the first CAG was generally performed more than 12 months after the onset of KD and also performed whenever chest pain or ECG abnormalities were observed during a medical check-up. As a result, CAG was performed on average at 1.67, 3.93, 5.12, and 6.52 years after the onset of KD.
The morphologic changes of the aneurysms were classified into persistent (PAN), regression (REG), localized stenosis (LS) and segmental stenosis (occlusion/recanalization) (OCC/REC). 22 Successive aneurysms partitioned from an originally long one were evaluated as a single entity. Therefore, a stenotic lesion in any of the partitioned aneurysms was regarded as stenotic transformation of the original aneurysm. Regression means that the lumen of the coronary artery where an aneurysm is located appears normal and does not mean normalization of the vascular structure. 23 As all patients in group (G) received prophylaxis, the time of OCC/REC in the patients with and without prophylaxis could not be compared.
According to the 3 main coronary arteries, the 4 types of acute-stage therapy, 4 types of prophylaxis and 4 types of transformation of the aneurysms at the convalescent stage could be divided into 192 groups. The groups that had enough subjects for statistically significant variation were compared with respect to the long-term outcomes.
Differences between 2 continuous variables, proved to reveal normal distribution by normal probability, were assessed by Student's t-test. Chi-square analysis was used to analyze 2×2 contingency tables. When the expectancy in the cells were less than 5, significant differences between groups were also assessed with Yates' continuity correction and also Fisher's direct test. Kaplan-Meier survival curve concerning the event-free rates among therapeutic regimens was assessed by log-rank test. A p-value<0.05 was considered to be statistically significant. Table 3 shows the results of the analyses. The overall observation periods ranged from 3 to 23 years after the onset of KD (mean, 9 years). The observation period for PAN was significantly longer than the interval between the onset of KD and the appearance of the stenotic lesions in all but aneurysms of the LAD in the group (A). For LAD aneurysms in the group (A), the observation periods for PAN 
Results

ANl
At the time of the final examination, 103 ANl were classified as either PAN (36, 35%), REG (11, 11%), LS (20, 19%) , or OCC/REC (36, 35%) .
Regression of ANI occurred at a significantly lower incidence than for ANm (ANI:ANm =11:37%, p<0.001). However, no LS was noted after regression. Furthermore, regression occurred at a comparatively early stage of KD (<1.6 years) compared with transformation into localized stenosis.
Although no significant difference was noted among the therapeutic regimens in the acute stage, regression occurred only with prophylaxis {a}.
Localized stenosis with prophylaxis {aw}, {a}, and {w} occurred at rates of 9%, 26%, and 17%, respectively (NS). Groups (S), (A), and (G) in the acute stage revealed LS rates of 20%, 23%, and 13%, respectively (NS). The LS rates in the LAD, LCX, and RCA were 17%, 0%, and 17%, respectively. Furthermore, no LS in the left coronary artery was noted in the group (G), which revealed a lower incidence for LS than the groups (S) and (A) (p<0.05) (Fig 1) . On the other hand, there was no significant difference in the rate of LS in the RCA among the therapeutic regimens; group (S): 36%, (A): 23%, and (G): 25%. The average time As mentioned earlier, neither LS nor OCC/REC was noted after REG. A significantly lower occlusion rate of aneurysms with prophylaxis (31% in the LAD, 52% in the RCA) than without (50% in the LAD, 92% in the RCA) was demonstrated in both the LAD (p<0.01) and the RCA (p<0.001). In comparison with the OCC/REC rates for each prophylactic regimen (Fig 2) , OCC/REC did not occur with prophylaxis {aw}, irrespective of therapy during the acute stage. Prophylaxis {aw} or {a} significantly lowered the incidence of occlusion, compared with prophylaxis {w} (p<0.005 and 0.05, respectively), and they also resulted in a significantly lower incidence than with prophylaxis {n} (p< 0.001). However, no significant difference was noted between prophylaxis {w} and prophylaxis {n}. Prophylaxis {aw}, even in the group (Non) in the acute stage showed a tendency toward a lower incidence than the group (S) without prophylaxis ( 2 =3.462; 2 =3.84, p<0.05). However, no significant difference was observed in the combination of prophylaxis {a} and any therapy in the acute stage (Fig 3) .
The therapeutic regimens that included too few patients to analyze statistically were those for OCC/REC and LS in the LCX, and REG in the RCA in the group (A), LS and RG in the LCX, and REG in the RCA in the group (S), OCC/REC in the 3 arteries, LS in both the LAD and the LCX, and REG in the LCA in the group (G).
ANm
At the time of the final examination, 46 ANm were classified as either PAN (20, 43%), REG (17, 37%), LS (9, 20%) and OCC/REC (0).
The REG rates for ANm in the groups (S), (A), (G), and (Non) in the acute stage were 20%, 31%, 65%, and 50%, respectively. The group (G) showed a significantly higher rate than the groups (A) and (S) (p<0.01, and p<0.001, respectively) (Fig 4) . Regressions of ANm occurred within 1.6 years after the onset of KD.
The LS rates for ANm were 20% in the group (S), 40% in the group (A), 14% in the group (G) and 50% in the group (Non) in the acute stage. Localized stenosis in the group (G) tended to be lower than in the group (A) (p<0.1) Kaplan-Meier survival curve with freedom from occlusion/recanalization of giant aneurysm: Combination therapy from the acute stage to the chronic stage (G+a = gamma globulin in the acute stage and aspirin after the acute stage; A+a = aspirin from the acute stage to the chronic stage; S+a = steroid in the acute stage and aspirin after the acute stage). Rates with freedom from occlusion/recanalization at the last observation for the therapeutic regimens G+a, A+a, and S+a were 75%, 71%, and 39%, respectively. Although the regimen of the group (S) in the acute stage and prophylaxis {a} showed a high incidence of occlusion/recanalization, no significant difference was observed among the 3 regimens.
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Furthermore, transformation of LS into OCC/REC was not observed during the observation period of 1-23 year after the onset (mean value =11 years).
The time to REG and LS of ANm was 1.19±0.56 years and 5.22±4.19 years after the onset of KD, respectively. Regression occurred faster than LS (p<0.05).
The therapeutic regimens that included too few patients to analyze statistically were those of LS in the LAD, REG and PAN in the LCX, and REG in the RCA in the group (A), PAN in both the LAD and the LCX, and LS and REG in the 3 arteries in the group (S), and LS in the 3 arteries, and REG and PAN in the LCX in the group (G).
ANs
At the time of the final examination, 13 ANs were classified as either PAN (1, 8%), REG (10, 77%), LS (2, 15%), or OCC/REC (0).
The The therapeutic regimens that included too few patients to analyze statistically were those of LS and PAN in the 3 arteries, and REG in the RCA in the groups (A) and (G).
Discussion
Long-term outcomes of coronary artery aneurysms in KD were clarified overall by Kato et al. 25 However, although tentative guidelines have been established regarding therapy after the convalescent stage of KD for coronary aneurysms, 8-10 there have not been any studies determining the long-term effect of prophylactic therapy in combination with acute-stage therapy.
Localized stenosis can be treated by drug administration, catheter intervention, or coronary artery bypass surgery, so it is occlusion of PAN that is the most serious complication to be prevented, although long-term management of the stenotic lesion is also important.
In the present study, no OCC/REC of ANl occurred with prophylaxis {aw}, which, together with prophylaxis {a}, significantly lowered the incidence than did no prophylaxis. The rates did not different among the therapies in the acute stage. In our study, warfarin therapy was not controlled by frequent thrombotest, so its therapeutic level may not have been maintained. However, it has been suggested that warfarin is effective in the primary prevention of cerebral thromboembolism, even if the international normalized ratio (INR) is not maintained at a therapeutic level. 26 A few years after the onset of KD, organization, recanalization and calcification of occlusive thrombi occurs, 13 so prevention of OCC/REC will result in prevention of mural thrombi and rapid massive coagulation. 13, 27 Furthermore, within 2 years after the acute stage of KD, platelet activation 28 and blood coagulation are promoted [29] [30] [31] and plasminogen-activator inhibitor-1 activity is decreased. 32, 33 Therefore, prophylaxis {aw} is considered to be effective for these processes.
The current direction of clinical trials assessing the optimal intensity of anticoagulation for children is to lower Fig 5. The S, A, G, and Non therapies are: S, A, G, and Non = steroids (5 cases), aspirin (15) , high-dose gamma globulin (7) , and nonspecific therapy (2) . The rate of localized stenosis in the group (G) was significantly lower than that in the group (A). (13), high-dose gamma globulin (17) , and non-specific therapy (2) . The group (G) demonstrated a significantly high rate of regression of aneurysms than did groups (A) and (S). the target INR range. 34 The daily warfarin dose of 0.1 mg/kg was almost same as that for children younger than 10 years of age in a study 35 that adopted a target INR of 1.5-2.5. Although the thrombotest is now being replaced by INR, it is valuable with respect to detecting an abnormality in the coagulation factor completely dependent on vitamin K. A thrombotest level of 27% is equivalent to INR of 1.5, 36 and the present study adopted a daily warfarin dose of 0.1 mg/kg, adjusted with the thrombotest approximately 30%.
Prophylaxis {aw} in our study prevented OCC/REC of ANl in which the blood flow was demonstrated to be slow by Doppler guidewire measurements. 37 In addition, the velocity wave in the RCA has less difference between the systolic and diastolic phases 38 and we hypothesize this is responsible for the higher incidence of OCC/REC. 4 In order to prevent this thrombosis, the prophylactic regimen of {aw} is necessary. Our study, demonstrating the benefit of warfarin, shows that the coagulation process plays an important role in thrombus formation in ANL, although we found that prophylaxis {w} resulted in a similar outcome to no prophylaxis, which means that warfarin alone is unable to prevent the thrombotic obstruction of ANl. The mechanism for venous thrombosis is mainly blood coagulation and stasis. Blood flow in a ANl is slow, such as those in a vein in which thrombosis is effectively prevented by warfarin. 37 The mechanism for thrombosis in the artery with rapid blood flow, on the other hand, is mainly platelet adhesion and aggregation. Both the inflow and outflow of a ANl is rapid, such as those in an artery in which thrombosis is effectively prevented by aspirin. 37 Therefore, antiobstructive prophylaxis for ANl requires both warfarin and aspirin. No OCC/REC occurred in ANm or ANs irrespective of the therapy, which may be related to the fact that, unlike ANl, 37 thrombosis was prevented because there was less endothelial exfoliation or injury, and also because the smaller aneurysms had flow patterns similar to arterial blood flow.
In ANl and ANm, the size of a PAN decreased by varying degrees because of intimal thickening as well as adhesion of mural thrombi. 3 Several cases of KD have been reported in which there was severe inflammation, and histologic examination of the ANl revealed the absence of the intimal and smooth muscle layers, or of intimal thickening. 39 In other words, migration of smooth muscle cells into the intima is minimal in the situation of absence or thinning of the media and therefore, intimal thickening does not occur. Prophylaxis {aw} resulted in PAN. Because OCC/REC appears 2.5±2.3 years after the onset of KD, prophylaxis {aw} is necessary for at least for the mean +1SD (5 years) followed by {a} for the prevention of LS.
In ANs, GG therapy with prophylaxis {a} was the most beneficial, which can be explained by the fact that GG attenuates endothelial injury and activation of the smooth muscle cells of media. 40, 41 The mechanism responsible for REG in ANm is thought to be essentially the same as that responsible for the reduction in size of persistent ANl. The high incidence of REG in the group (G) can be explained by the lower rate of LS, as well as a reflection of the size of the PAN. Regression is generally maintained. It has recently been reported that, unlike LS, abnormal expression of vascular growth factors, cytokines, and chemokines in the arterial wall is not recognized in the late stage of KD. 42 Thus, maintenance of normal vessel geometry is caused by suspension of the remodeling process through normalization of the shear stress. Further-more, mild stenosis caused by excessive intimal thickening may be reversed through dilatation by a specific mechanism. 43 Autopsy findings have determined that LS of ANl is caused by endothelial proliferation and intimal thickening at the inlet and outlet of the aneurysm, 13 related to platelet aggregation caused by decreases in shear stress within the aneurysm through the binding of fibrinogen and GPIIb/IIIa complex, which induces adhesion molecule expression, as well as vascular growth factor, cytokine, and chemokine production within endothelial cells. As a result of the increased blood flow velocity at the inlet and outlet of the ANl, high shear stress causes direct endothelial injury and exfoliation and platelet aggregation through binding of von Willebrand factor, GPIb and, GPIIb/IIIa. 44 Smooth muscle cells in the neighboring vascular wall increase their expression of vascular growth factors, cytokines, and chemokines because of the increased stretch, which also promotes proliferation and migration to the intima. 45, 46 Unlike the adaptive regulation during regression of aneurysms, this process is thought to be maintained for a long period. The fact that prophylaxis {aw} decreased the incidence of LS as well as that of OCC/REC can be explained by decreased proliferation of smooth muscle cells in the media because of decreased platelet adhesion and thrombin production. 47 No transformation of LS to OCC/REC occurred in the LCA irrespective of therapy in the acute stage, which may be explained by the fact that LS occurs more slowly in the LCA. 4, 24 
Study Limitations
The major limitations of this study were its retrospective nature and the relative small number of patients in each subgroup. However, it is considered that the bias was minimized by the groups comprising 2 types of patients: those from randomized control studies, and the others treated with a fixed regimen in each time period. Thus, our results suggest management strategies for patients in the interim, and an insight to the treatment of KD as a combination of acute-stage therapy and prophylactic therapy. Future clinical trials evaluating this therapeutic combination on the transformation of aneurysms are warranted.
Conclusions
High-dose GG therapy in the acute stage of KD is the first choice for preventing the development of ANl, as well as stenotic transformation. If a ANl does develop, prophylaxis {aw} is recommended for the first 2.5±2.3 years, followed by {a}, irrespective of the existence of LS. Once the lumen normalizes, prophylaxis may be unnecessary, irrespective of the original size of the aneurysm.
